<DOC>
	<DOCNO>NCT02245958</DOCNO>
	<brief_summary>This study retrospective chart review evaluate dos botulinum Type A toxins BOTOX® ( onabotulinumtoxinA ) Xeomin® ( incobotulinumtoxinA ) use treatment Cervical Dystonia Blepharospasm clinical practice .</brief_summary>
	<brief_title>A Retrospective Chart Review BOTOX® Xeomin® Management Cervical Dystonia Blepharospasm</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Confirmed primary diagnosis idiopathic cervical dystonia blepharospasm least 2 year Treatment Xeomin® BOTOX® least 2 year . Having neuromuscular junction transmission disorder take medication could affect neuromuscular junction transmission Previous surgical procedure involve bone muscle management cervical dystonia blepharospasm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>